1. Home
  2. NGNE vs ARL Comparison

NGNE vs ARL Comparison

Compare NGNE & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$18.30

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Logo American Realty Investors Inc.

ARL

American Realty Investors Inc.

BUY

Current Price

$17.10

Market Cap

277.0M

Sector

Real Estate

ML Signal

BUY

Company Overview

Basic Information
Metric
NGNE
ARL
Founded
2003
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Building operators
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
327.8M
277.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NGNE
ARL
Price
$18.30
$17.10
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$40.14
N/A
AVG Volume (30 Days)
152.7K
2.0K
Earning Date
11-13-2025
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.36
Revenue
N/A
$49,060,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$47.95
Revenue Growth
N/A
N/A
52 Week Low
$6.88
$9.43
52 Week High
$37.27
$17.37

Technical Indicators

Market Signals
Indicator
NGNE
ARL
Relative Strength Index (RSI) 45.81 60.44
Support Level $18.12 $16.01
Resistance Level $20.44 $17.37
Average True Range (ATR) 1.23 0.42
MACD 0.23 0.11
Stochastic Oscillator 48.61 84.30

Price Performance

Historical Comparison
NGNE
ARL

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About ARL American Realty Investors Inc.

American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.

Share on Social Networks: